» Articles » PMID: 25243372

Fitness Impaired Drug Resistant HIV-1 is Not Compromised in Cell-to-cell Transmission or Establishment of and Reactivation from Latency

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2014 Sep 23
PMID 25243372
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Both the presence of latently infected cells and cell-to-cell viral transmission are means whereby HIV can partially evade the inhibitory activities of antiretroviral drugs. The clinical use of a novel integrase inhibitor, dolutegravir (DTG), has established hope that this compound may limit HIV persistence, since no treatment-naïve patient treated with DTG has yet developed resistance against this drug, even though a R263K substitution in integrase confers low-level resistance to this drug in tissue culture. Here, we have studied the impact of R263K on HIV replication capacity and the ability of HIV to establish or be reactivated from latency and/or spread through cell-to-cell transmission. We affirm that DTG-resistant viruses have diminished capacity to replicate and establish infection. However, DTG-resistant viruses were efficiently transmitted via cell-to-cell contacts, and were as likely to establish and be reactivated from latent infection as wildtype viruses. Both cell-to-cell transmission of HIV and the establishment of and reemergence from latency are important for the establishment and maintenance of viral reservoirs. Since the DTG and other drug-resistant viruses studied here do not seem to have been impaired in regard to these activities, studies should be undertaken to characterize HIV reservoirs in patients who have been treated with DTG.

Citing Articles

Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations.

Hikichi Y, Van Duyne R, Pham P, Groebner J, Wiegand A, Mellors J mBio. 2021; 12(1).

PMID: 33436439 PMC: 7844542. DOI: 10.1128/mBio.03134-20.


Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle.

Van Duyne R, Kuo L, Pham P, Fujii K, Freed E Proc Natl Acad Sci U S A. 2019; 116(18):9040-9049.

PMID: 30975760 PMC: 6500141. DOI: 10.1073/pnas.1820333116.


The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.

Mesplede T, Leng J, Pham H, Liang J, Quan Y, Han Y mBio. 2017; 8(2).

PMID: 28377526 PMC: 5380839. DOI: 10.1128/mBio.00157-17.


New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif.

Smith S, Derdeyn C J Virol. 2017; 91(9).

PMID: 28250119 PMC: 5391458. DOI: 10.1128/JVI.00149-17.


Combination antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human immunodeficiency virus-1.

Titanji B, Pillay D, Jolly C J Gen Virol. 2017; 98(4):821-834.

PMID: 28141491 PMC: 5657029. DOI: 10.1099/jgv.0.000728.


References
1.
Pennings P . HIV Drug Resistance: Problems and Perspectives. Infect Dis Rep. 2014; 5(Suppl 1):e5. PMC: 3892620. DOI: 10.4081/idr.2013.s1.e5. View

2.
Jolly C, Kashefi K, Hollinshead M, Sattentau Q . HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med. 2004; 199(2):283-93. PMC: 2211771. DOI: 10.1084/jem.20030648. View

3.
Mesplede T, Quashie P, Zanichelli V, Wainberg M . Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann Med. 2014; 46(3):123-9. DOI: 10.3109/07853890.2014.883169. View

4.
Quashie P, Mesplede T, Wainberg M . HIV Drug Resistance and the Advent of Integrase Inhibitors. Curr Infect Dis Rep. 2012; 15(1):85-100. DOI: 10.1007/s11908-012-0305-1. View

5.
Dimitrov D, Willey R, Sato H, Chang L, Blumenthal R, Martin M . Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol. 1993; 67(4):2182-90. PMC: 240333. DOI: 10.1128/JVI.67.4.2182-2190.1993. View